Comparison between 0.5% Timolol Maleate and 0.2% Brimonidine Tartrate in controlling increase in intraocular pressure after Neodymium: Yttrium-Aluminium-Garnet laser iridotomy.
Abstract
AIM: To compare the effectiveness of prophylactically given 0.5% Timolol maleate and 0.2% Brimonidine tartrate in controlling the increase of intraocular pressure after Nd:YAG laser iridotomy.
MATERIALS AND METHODS: 70 patients in two equal groups were studied at Department of Ophthalmology, Jinnah Hospital, Lahore from 01-07-2011 to 31-12-2012. It was a Quasi-experimental study, non–probability purposive sampling was done. Group A was an experimental group which received 0.2% Brimonidine tartrate and group B was control group which received 0.5% Timolol maleate 1 hour before the laser treatment.
RESULTS: In our study the mean age was calculated to be 46.38 ± 7.56 years, out of 70 patients, male patients were 54.29% (n=19) in Group-A and 60% (n=21) in Group-B, while female patients were 45.71% (n=16) in Group-A and 40% (n=14) in Group-B, mean intraocular pressure was recorded as 20.54 ± 2.43 in Group-A and 18.31 ± 2.15 in Group-B respectively, comparison of effectiveness in both groups was recorded as 34.29% (n=12) in Group-A and 71.43% (n=25) in Group-B. 65.22% (n=23) in Group-A and 28.57% (n=10) in Group-B did not show efficacy, p value was calculated as 0.002 which shows significant difference in both groups.
CONCLUSION: We concluded that 0.5% Timolol maleate is more effective than 0.2% Brominidine tartrate in controlling increase in intraocular pressure following Nd:YAG laser iridotomy.
KEYWORDS: Intra ocular pressure, Nd:YAG laser iridotomy, 0.5% Timolol maleate, 0.2% Brimonidine tartrate.
Downloads
Published
Issue
Section
License
OWNERSHIP OF COPYRIGHT
The copyright in this website and the material on this website (including without limitation the text, computer code, artwork, photographs, images, music, audio material, video material and audio-visual material on this website) is owned by OPHTHALMOLOGY PAKISTAN.
Â
COPYRIGHT LICENSE
OPHTHALMOLOGY PAKISTAN grants to you a worldwide non-exclusive royalty-free revocable license to:
a) view this website and the material on this website on a computer or mobile device via a web browser;
b) copy and store this website and the material on this website in your web browser cache memory; and
c) print pages from this website for your use.
d) OPHTHALMOLOGY PAKISTAN permits all published articles to be copied, redistributed, remixed, transmitted and the work be adapted provided the original work and source is appropriately cited.
OPHTHALMOLOGY PAKISTAN does not grant any other rights in relation to this website or the material on this website. In other words, all other rights are reserved.
For the avoidance of doubt, you must not adapt, edit, change, transform, publish, republish, distribute, redistribute, broadcast, rebroadcast or show or play in public this website or the material on this website (in any form or media) without appropriately and conspicuously citing the original work and source or OPHTHALMOLOGY PAKISTAN prior written permission.
Â
PERMISSIONS
You may request permission to use the copyright materials on this website by writing to chiefeditor@ophthalmologypakistan.com.
Â
ENFORCEMENT OF COPYRIGHT
OPHTHALMOLOGY PAKISTAN takes the protection of its copyright very seriously.
If OPHTHALMOLOGY PAKISTAN discovers that you have used its copyright materials in contravention of the license above, OPHTHALMOLOGY PAKISTAN may bring legal proceedings against you seeking monetary damages and an injunction to stop you using those materials. You could also be ordered to pay legal costs.
If you become aware of any use of OPHTHALMOLOGY PAKISTAN' copyright materials that contravenes or may contravene the license above, please report this by email to chiefeditor@ophthalmologypakistan.com.
Infringing material
If you become aware of any material on the website that you believe infringes your or any other person's copyright, please report this by email to chiefeditor@ophthalmologypakistan.com.